The HBV market is clearly undeserved but most HBV patients are Chinese who cannot afford expensive medicine.
Chinese in coastal China (e.g. Shanghai) can afford medicine. Chinese in Hong Kong can afford medicine. Chinese in Taiwan can afford medicine. Chinese in the New York City borough of Queens can afford medicine. In other words, I think your assertion is unduly simplistic.